Understand the source comparison
Best Peptides to Break Through Weight Loss Plateau Ranked: Mechanism Comparison
Before selecting a peptide for plateau intervention, understand how each class addresses the specific mechanisms driving metabolic adaptation. This table ranks peptides by their primary mechanism, clinical evidence strength, and suitability for different plate
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide for plateau intervention, understand how each class addresses the specific mechanisms driving metabolic adaptation. This table ranks peptides by their primary mechanism, clinical evidence strength, and suitability for different plateau profiles.
- Survodutide
- Dual GLP-1/glucagon agonist. Suppresses appetite while increasing hepatic thermogenesis
- Phase 2 trials show 18.6% mean weight loss at 48 weeks in prior GLP-1 non-responders
- Plateaus caused by metabolic adaptation to single-agonist GLP-1 therapy
- 24–48 weeks with dose titration
- Most effective for patients who plateaued on semaglutide or tirzepatide. Addresses both gastric and metabolic slowdown
- MK 677
- Ghrelin mimetic. Stimulates endogenous GH and IGF-1 secretion
- Documented 97% increase in 24-hour GH secretion and 60% IGF-1 elevation in JCEM trial
- Plateaus driven by muscle loss or suppressed lipolysis during prolonged deficits
- 12–16 weeks with 4-week washout before repeat cycles
- Best for preserving lean mass during aggressive fat loss. Prevents metabolic slowdown from muscle catabolism
- CJC-1295/Ipamorelin
- GHRH analog + selective GH secretagogue. Pulsatile GH release without cortisol elevation
- Multiple studies confirm lean mass preservation and fat oxidation without adrenal stress
- Plateaus with concurrent muscle loss or low GH pulsatility
- 8–12 weeks as part of a structured fat loss phase
- Ideal for patients prioritizing body composition over scale weight. Restores anabolic signaling
- Tesofensine
- Triple monoamine reuptake inhibitor. CNS-mediated appetite suppression and thermogenesis
- Phase 3 data: 10.6% weight loss at 24 weeks in prior non-responders to orlistat/sibutramine
- Plateaus unresponsive to peripheral GLP-1 mechanisms or caused by reward-driven eating
- 12–24 weeks under medical supervision
- Works when GLP-1 agonists fail. Addresses central appetite dysregulation not resolved by gastric mechanisms
- Mazdutide
- Dual GLP-1/glucagon agonist with balanced receptor affinity
- Phase 2 trials show sustained weight loss beyond 40 weeks with minimal GI side effects
- Plateaus requiring both appetite control and metabolic rate support
- 24–52 weeks with structured titration
- Strong choice for long-term plateau intervention. Dual mechanism prevents adaptation
- Thymalin
- Thymus-derived peptide. Supports thyroid axis and mitochondrial function
- Preclinical and observational data; limited large-scale RCTs
- Plateaus driven by suppressed T3 conversion or immune-mediated metabolic slowdown
- 4–8 week cycles with 4-week breaks
- Adjunct compound. Works best stacked with GLP-1 or GH protocols to address thyroid suppression